Skip to main content
TipRanks
Go Ultimate75% OFF

Renalytix (RNLXY) AI Stock Analysis

238 Followers
RNLXY

Renalytix

(Other OTC:RNLXY)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Innovative Product OfferingRenalytix's use of machine learning in diagnostics positions it as a leader in innovative kidney disease management, potentially driving long-term growth.
Negative Factors
Financial DistressOngoing financial distress with negative equity and losses threatens long-term viability, requiring urgent strategic restructuring for recovery.

Renalytix (RNLXY) vs. SPDR S&P 500 ETF (SPY)

-80%-60%-40%-20%0%20%RNLXY-20.67%SPY+15.52%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$47.84M
Dividend Yield
―
Average Volume (3M)
3,746
Price to Earnings (P/E)
-2.0
Beta (1Y)
0.88
Revenue Growth
―
EPS Growth
―
Country
US
Employees
60
Sector
Healthcare
Sector Strength
51
Industry
Healthcare Providers & Services

Renalytix Business Overview & Revenue Model

Company Description

Renalytix AI PLC is a developer of artificial intelligence-enabled clinical decision support solutions for kidney disease and costly chronic medical conditions globally. The company's solutions are being designed to make significant improvements in k...

How the Company Makes Money

Renalytix generates revenue primarily through the sale of its diagnostic products and services to healthcare providers, hospitals, and clinical laboratories. The company's flagship product, KidneyIntelX, is a diagnostic platform that uses machine lea...

Renalytix Earnings Call Summary

Earnings Call Date:Mar 18, 2025(Q2-2025)|% Change Since:-30.37%|Next Earnings Date:Nov 25, 2020
Earnings Call SentimentPositive

The earnings call presented a positive outlook for Renalytix, with significant achievements in FDA approval, Medicare reimbursement, and revenue growth. Operational improvements and strategic partnerships further enhance their position. However, resource constraints and initial market dependency present challenges. Overall, the positive developments and growth potential outweigh the challenges.

Positive Updates

FDA Approval and Medicare Reimbursement
Renalytix's KidneyIntelX test received FDA approval, becoming the first-ever FDA-approved breakthrough designation prognostic test for kidney disease. It is fully Medicare reimbursed at $950 per test.

Negative Updates

Small Team and Resource Limitations
The company is constrained by a small team of eight salespeople, which affects their ability to rapidly expand and scale operations.

Company Guidance

During the Renalytix Investor Presentation, several key metrics and strategic goals were outlined. The company has achieved a 20% quarter-on-quarter revenue growth, with expectations to reach $3.2 million in revenue for the fiscal year, $8.4 million the following year, and $17 million subsequently. The commercial testing volume increased from 60% to 82%, with Medicare reimbursing $950 per test. Renalytix has reduced administrative fees by 50% and decreased order cancellation rates from 24% to 8%. It also improved test turnaround time to under seven days and reduced billing to insurance payment time by 65%. Additionally, Renalytix aims for a 1% U.S. market penetration, equivalent to 150,000 tests annually. The company is focusing on expanding insurance partnerships, with 52% of testing now Medicare and Medicare Advantage patients, and is investing in strategic partnerships, including with pharma companies, to enhance its competitive positioning.

Renalytix Technical Analysis

Technical Analysis SentimentNeutral
Last Price3.57

Price Trends

50DMA3.80Negative
100DMA3.06Positive
200DMA2.45Positive

Market Momentum

MACD-0.01Positive
RSI44.13Neutral
STOCH-0.30Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RNLXY, the sentiment is Neutral. The current price of 3.57 is below the 20-day moving average (MA) of 3.69, below the 50-day MA of 3.80, and above the 200-day MA of 2.45, indicating a neutral trend. The MACD of -0.01 indicates Positive momentum. The RSI at 44.13 is Neutral, neither overbought nor oversold. The STOCH value of -0.30 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for RNLXY.

Renalytix Risk Analysis

Renalytix disclosed 91 risk factors in its most recent earnings report. Renalytix reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Renalytix Peers Comparison

Overall Rating

Financial Indicators

RNLXY against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%

* Healthcare Sector Average

Performance Comparison

-60%-40%-20%0%RNLXYDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
RNLXY and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
RNLXYRenalytix Plc3.57-0.78-17.86%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.